Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KET01 add-on trial in treatment-resistant depression
2021-004927-34Phase 2Completed
- Sponsor
- Ketabon
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by Ketabon. Started Dec 2021; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2021-004927-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004927-34.